ChemoCentryx

Biopharma’s 5 Biggest M&A Deals of 2022
Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
M&A
Amgen
Horizon Therapeutics
Pfizer
Biohaven
Global Blood Therapeutics
Bristol Myers Squibb
Turning Point Therapeutics
ChemoCentryx
Flag link:
SITC 2022 preview – cytokines and oral checkpoints
SITC 2022 preview – cytokines and oral checkpoints
EP Vantage
SITC
Incyte
ChemoCentryx
Amgen
cytokines
Flag link:
No big bang for biopharma buyouts
No big bang for biopharma buyouts
EP Vantage
M&A
Pfizer
Global Blood Therapeutics
Amgen
ChemoCentryx
Novo Nordisk
Forma
Alcon
Aerie Pharmaceuticals
Gilead Sciences
MiroBio
Flag link:
Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence
Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence
Fierce Pharma
Amgen
M&A
patent cliff
ChemoCentryx
Flag link:
Big Pharma Is Going Holiday Shopping. Who's Next?
Big Pharma Is Going Holiday Shopping. Who's Next?
Motley Fool
Big Pharma
M&A
ChemoCentryx
Epizyme
Magenta Therapeutics
Flag link:
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
Motley Fool
ChemoCentryx
Ocular Therapeutics
Axsome Therapeutics
Flag link:
Flash FDA approval sends ChemoCentryx spiralling upwards
Flash FDA approval sends ChemoCentryx spiralling upwards
Pharmaforum
ChemoCentryx
FDA
avacopan
Tavneos
ANCA-positive vasculitis
Flag link:
The big approvals still on the cards for 2021
The big approvals still on the cards for 2021
EP Vantage
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Flag link:
Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug
Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug
Endpoints
FDA
advisory panels
ChemoCentryx
avacopan
ANCA-positive vasculitis
Flag link:
Chemocentryx takes a leap of faith with avacopan
Chemocentryx takes a leap of faith with avacopan
EP Vantage
ChemoCentryx
avacopan
clinical trials
hidradenitis suppurativa
Flag link:
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
BioSpace
ChemoCentryx
Vifor Fresenius Medical Care Renal Pharma
avacopan
ANCA-positive vasculitis
clinical trials
Flag link:
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Endpoints
pancreatic cancer
ChemoCentryx
CCX872
Flag link:
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
Bidness Etc.
ChemoCentryx
CCX168
orphan drugs
aHUS
Flag link:
Five Small Biotech Stocks Analysts Think Will Triple
Five Small Biotech Stocks Analysts Think Will Triple
Forbes
Arrowhead Research
ChemoCentryx
Ziopharm
TherapeuticsMD
Dynavax
Flag link:
3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week
Motley Fool
Neurocrine Biosciences
ChemoCentryx
GSK
Avanir
Flag link:
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Neurocrine
ChemoCentryx
CCX140
NBI-98854
tardive dyskinesia
diabetic nephropathy
Flag link:
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
TheStreet.com
ChemoCentryx
diabetic nephropathy
CCX140
Flag link:
The Impact of a Failed Crohn's Disease Trial Study
The Impact of a Failed Crohn's Disease Trial Study
Motley Fool
Crohn's Disease
Vercirnon
ChemoCentryx
GSK
Flag link:
3 Horrendous Health-Care Stocks This Week
3 Horrendous Health-Care Stocks This Week
Motley Fool
ChemoCentryx
Aglos Pharmaceuticals
Prosensa
Flag link:
GSK's Crohn's disease treatment fails in Phase III trial
GSK's Crohn's disease treatment fails in Phase III trial
Reuters
GSK
Crohn's Disease
ChemoCentryx
Vercirnon
Flag link:

Pages